Peirce Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$500K Buy
432
+29
+7% +$34.2K 0.18% 36
2026
Q2
$483K Buy
403
+26
+7% +$26.6K 0.18% 35
2026
Q1
$347K Hold
377
– – 0.14% 39
2025
Q4
$405K Sell
377
-35
-8% -$33.5K 0.16% 36
2025
Q3
$314K Hold
412
– – 0.13% 35
2025
Q2
$321K Hold
412
– – 0.14% 37
2025
Q1
$340K Hold
412
– – 0.17% 30
2024
Q4
$318K Hold
412
– – 0.16% 31
2024
Q3
$365K Hold
412
– – 0.18% 27
2024
Q2
$373K Hold
412
– – 0.2% 28
2024
Q1
$321K Sell
412
-33
-7% -$23.5K 0.18% 32
2023
Q4
$259K Buy
+445
New +$260K 0.16% 36

Other funds holding LLY

Peirce Capital Management's LLY Position: Q3 2026 in Review

Peirce Capital Management increased its Eli Lilly (LLY) stake by 7.2% in Q3 2026, buying an estimated $34.2K and bringing the position to 432 shares worth $500K. The position accounts for 0.18% of the portfolio, ranked #36.

Peirce Capital Management first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Peirce Capital Management held 432 shares of Eli Lilly worth $500K as of Q3 2026.
  • Peirce Capital Management bought 29 Eli Lilly shares in Q3 2026, an estimated $34.2K.
  • Eli Lilly made up 0.18% of Peirce Capital Management's portfolio in Q3 2026, its #36 holding.
  • Peirce Capital Management first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Peirce Capital Management's 13F filing for Q3 2026, filed 19 Oct 2026.